RT Book, Section
A1 Hooker, Jared
A1 Baber, Omar
A1 Baber,  Usman
A2 Fuster, Valentin
A2 Narula, Jagat
A2 Vaishnava, Prashant
A2 Leon, Martin B.
A2 Callans, David J.
A2 Rumsfeld, John S.
A2 Poppas, Athena
SR Print(0)
ID 1202453209
T1 Heart Disease in Chronic Kidney Disease
T2 Fuster and Hurst's The Heart, 15e
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264257560
LK accesscardiology.mhmedical.com/content.aspx?aid=1202453209
RD 2024/04/24
AB Content  UpdateEMPA-KIDNEY:  Empagliflozin  and  Chronic  Kidney  DiseaseThe  EMPA-KIDNEY  trial  was  an  international,  randomized,  parallel-group,  double-blind,  placebo-controlled,  clinical  trial  designed  to  assess  the  effect  of  10  mg  once  daily  empagliflozin  treatment  on  the  progression  of  chronic  kidney  disease  (CKD)  and  cardiovascular  disease  and  to  examine  the  safety  profile  of  the  drug  in  a  wide  range  of  patients  with  CKD.  Read  More